U.S. Markets open in 1 hr 5 mins
  • Gold

    1,768.00
    -0.30 (-0.02%)
     
  • EUR/USD

    1.1614
    +0.0013 (+0.1161%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • Vix

    17.49
    +0.63 (+3.74%)
     
  • GBP/USD

    1.3740
    +0.0063 (+0.4603%)
     
  • USD/JPY

    114.1570
    +0.4800 (+0.4222%)
     
  • BTC-USD

    61,090.20
    +257.32 (+0.42%)
     
  • CMC Crypto 200

    1,431.30
    +24.56 (+1.75%)
     
  • FTSE 100

    7,203.94
    -30.09 (-0.42%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

Novavax (NVAX) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Novavax (NVAX) closed the most recent trading day at $230.29, moving +1.49% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.08%.

Heading into today, shares of the vaccine maker had lost 9.59% over the past month, lagging the Medical sector's loss of 2.33% and the S&P 500's loss of 1.81% in that time.

NVAX will be looking to display strength as it nears its next earnings release. On that day, NVAX is projected to report earnings of -$4.04 per share, which would represent a year-over-year decline of 25.86%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $306.8 million, up 95.39% from the year-ago period.

Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$8.37 per share and revenue of $1.77 billion. These totals would mark changes of -15.13% and +273.17%, respectively, from last year.

Investors should also note any recent changes to analyst estimates for NVAX. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 3.86% lower within the past month. NVAX is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 196, putting it in the bottom 23% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novavax, Inc. (NVAX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research